Epigenetics provides a new generation of oncogenes and tumour-suppressor genes

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Cancer is increasingly understood as a genetic and epigenetic disease.
• While oncogenes and tumor suppressors are well-studied, the role of epigenetic alterations in cancer is a growing focus.
• Epigenetic disruptions, including DNA methylation and histone modification, are hallmarks of human cancers.

Purpose of the Study:

• To investigate whether epigenetic genes themselves are driving forces in tumorigenesis.
• To explore the link between epigenetic gene dysfunction and cancer development.
• To identify novel molecular targets for cancer therapies based on epigenetic alterations.

Main Methods:

• Analysis of knockout mice models with defects in DNA methyltransferases, methyl-CpG-binding proteins, and histone methyltransferases.
• Examination of human tumors for somatic mutations, deletions, and silencing of epigenetic regulators like histone acetyltransferases, histone methyltransferases, and chromatin remodelers.
• Investigation of cancer-prone families with germline mutations in epigenetic genes, such as hSNF5/INI1.

Main Results:

• Defects in epigenetic genes in mice significantly impact cancer onset risk.
• Human tumors exhibit alterations in epigenetic genes, including mutations and silencing.
• Germline mutations in epigenetic genes are linked to inherited cancer predisposition.

Conclusions:

• Epigenetic genes play a crucial role in cancer development and can act as oncogenes or tumor suppressors.
• These findings highlight novel molecular targets for cancer treatment.
• Epigenetic therapies, such as DNA-demethylating agents and histone deacetylase inhibitors, show promise in clinical settings, particularly for hematological malignancies.